Skip to main content
. 2004 Jul 10;54(2):172–178. doi: 10.1007/s00262-004-0575-z

Table 5.

Distribution of inhibitory KIRs/HLA-C ligands in the absence of the corresponding activating KIRs in melanoma patients and healthy controls

KIR Ligands Frequency
Patients Controls
KIR2DL2/2DL3 HLA-CAsn80 7 (38.9%) 3 (18.8%)
KIR2DL1 HLA-CLys80 3 (60.0%) 11 (68.8%)
KIR2DL1; KIR2DL2/2DL3 HLA-CLys80;Asn80 12 (46.2%) 7 (33.3%)